MedTrace Logo

How TENS Affects Pain, Medication Use, and Muscle Function in Older Adults With Hip Fractures

NCT07567339 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-08

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if transcutaneous electrical nerve stimulation (TENS) can reduce perioperative pain in older adults with hip fractures. It will also evaluate its effects on physiological and psychological outcomes. The main questions it aims to answer are:

Does adding TENS to usual care during the preoperative phase reduce pain intensity and analgesic consumption? Does TENS affect pressure pain threshold and vital signs (blood pressure, heart rate, and respiratory rate)?

Researchers will compare active TENS to sham TENS (no perceptible stimulation) to see if TENS is effective in reducing pain and improving related outcomes.

Participants will:

* Undergo a standardized baseline assessment, including evaluation of pain, vital signs, anxiety, discomfort, and pressure pain threshold
* Complete questionnaires assessing quality of life, physical activity, depressive symptoms, anxiety, fear of falling, and pain catastrophizing
* Be randomly assigned to receive either active TENS or sham TENS
* Receive a single 45-minute TENS session
* Have their analgesic use recorded for the 24 hours before and after the intervention.

Conditions

  • Hip Fractures
  • Femoral Neck Fractures
  • Intertrochanteric Femur Fracture

Interventions

DEVICE

Active Transcutaneous Electrical Nerve Stimulation (TENS)

Active transcutaneous electrical nerve stimulation (TENS) will be applied for 45 minutes, with intensity adjusted to the maximum level tolerated by the participant.

DEVICE

Sham Transcutaneous Electrical Nerve Stimulation (Sham TENS)

Sham transcutaneous electrical nerve stimulation (TENS) will be applied for 45 minutes, with intensity set at a sub-sensory level, with no perceptible stimulation.

Sponsors & Collaborators

  • University of the Sinos Valley

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-22
Primary Completion
2026-12-28
Completion
2027-01-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07567339 on ClinicalTrials.gov